Transforming the future of diagnostics with AI-powered biosensor assays

Delivering Bespoke, Cost-Effective Diagnostics

Quality in, Quality out: Beginning from the Sensor.

LumaCell technology is at the forefront of the development of GPCR-based diagnostics. Leveraging AI & ML, from a generated custom designed sensor to the interpretation and analysis of the large data sets inherent to biology, our competitive edge lies in offering a full stack diagnostic solution. Unlike many AI enterprises, we began with optimizing our hardware to improve data input quality for more reliable and actionable insights.

First Application

LumaCell will bridge the gap between drug impairment laws and available screening technology, allowing a precise way to determine active impairment from THC.

Next Steps

Develop new ways to manage debilitating chronic diseases like Type 2 diabetes and chronic pain by facilitating the real-time measurement of therapeutics like GLP-1 agonists and Cannabinoids.

The Future

LumaCell is resolutely poised to ascend as a dominant force in the discovery and repurposing of GPCR-targeting pharmaceuticals, a critical sector that encompasses over one-third of the global drug market.

LumaCell’s Platform: The Lab in a Cell

Genetically-modified yeast cells that are easy to utilize, adaptable, and cost-efficient to produce.

The Road Ahead

Deeper physiological insights.

LumaCell is adeptly positioned to harness the growth of this therapeutic class, streamlining and enhancing molecular detection & metabolic wellness.

Impairment Detection

Ever thought about losing your job because of a glass of wine from two weeks back? That’s been the drill with cannabis testing for years. But as the era evolves, and so does to the legalization surrounding cannabis. We’ve crafted a product that zeroes in on active THC, keeping pace with new laws and court decisions.

Optimizing Therapeutics

Our goal is to create a convenient at-home panel for monitoring GLP-1, GIP, and Glucagon levels, enabling direct therapeutic monitoring. This approach will allow for personalized optimization of dosing and timing based on an individual’s metabolic profile. The panel will encompass both current and next-generation agonists being developed by pharmaceutical leaders underscoring the significance of this emerging class of therapeutics.

We also aim to investigate the synergistic mechanisms of action (MoA) involving cannabinoids to enhance the tolerability and effectiveness of GLP-1 agents such as Semaglutide.

Unlocking the Boundless Potential of GPCRs

A Glimpse into the Reach of LumaCell’s Opportunities.

Around 1/3 of all pharmaceuticals sold today target the GPCR class of receptors, including most recently GLP-1 peptides. Only about 120 out of the 800 have identified ligands and function, leaving significant room for exploration and application. Every Receptor shown here has the potential to become a Market.

(Red indicates an established target. Green indicates trial targets, with later-stage trials showing darker green.)